XOMA Corporation engages in the discovery and development of antibody-based therapeutics in the United States, Europe, and the Asia Pacific. It offers ACEON, an angiotensin converting enzyme inhibitor. The company is developing its lead product gevokizumab (IL-1 beta modulating antibody) through a Phase III program in non-infectious uveitis and proof-of-concept studies in other IL-1-mediated diseases; XOMA 3AB, a bio defense anti-botulism product candidate, which is in Phase I trial for the treatment of Type A botulinum neurotoxins; and preclinical programs for the treatment of autoimmune, cardio-metabolic, infectious, inflammatory, and oncological diseases. It also provides insulin receptor-activating antibodies, such as XMetA, which provides insulin-like activity to diabetic patients; and insulin receptor-sensitizing antibodies, including XMetS that reduces insulin resistance of diabetic patients. In addition, the company develops FDC1, a perindopril arginine and amlodipine besylate that is Phase III trials for the treatment of hypertension; HCD122 and LFA102 antibodies, which are in Phase I and/or II clinical trials for the treatment of hematologic tumors, and breast and prostate cancers; and HE monoclonal antibody that is in Phase II and I trials for the treatment of non-small cell lung cancer, solid tumors, and multiple myeloma. Further, it licenses antibody discovery, optimization, and development technologies, such as Antibody Discovery Advanced Platform Technologies; ModulX technology that enables positive and negative modulation of biological pathways; and OptimX technologies. That company has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; SRI International; Takeda Pharmaceutical Company Limited; Arana Therapeutics Limited; Novartis AG; Kaketsuken; AVEO Pharmaceuticals, Inc.; Genentech, Inc; and UCB Celltech. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.